What is synchronous oligometastatic non-small cell lung cancer?

Lung cancer accounts for one-quarter of all cancer deaths and remains as the dominant contributor to cancer mortality despite steady, continuous decline in incidence (1). Management of non-small cell lung cancer (NSCLC), which accounts for approximately 85% of lung cancer, is therefore one of the most actively investigated fields to improve patient outcomes.